Aged < 40 years, n (%) | Placebo (n = 597) | Erenumab 70 mg (n = 514) | Erenumab 140 mg (n = 382) | Erenumab 70 + 140 mg (n = 896) | Total (N = 1493) |
Participants with CV/ cerebrovascular TEAEs | 12 (2.0) | 7 (1.4) | 10 (2.6) | 17 (1.9) | 29 (2.0) |
Palpitations | 2 (0.3) | 2 (0.4) | 3 (0.8) | 5 (0.6) | 7 (0.5) |
Hypertension | 2 (0.3) | 3 (0.6) | 0 | 3 (0.3) | 5 (0.3) |
Hot flush | 2 (0.3) | 0 | 2 (0.5) | 2 (0.2) | 4 (0.3) |
Flushing | 1 (0.2) | 0 | 1 (0.3) | 1 (0.1) | 2 (0.1) |
Bundle branch block right | 0 | 1 (0.2) | 0 | 1 (0.1) | 1 (0.1) |
Cardiac flutter | 0 | 0 | 1 (0.3) | 1 (0.1) | 1 (0.1) |
Diastolic hypertension | 0 | 0 | 1 (0.3) | 1 (0.1) | 1 (0.1) |
Haematoma | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Hypotension | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Junctional ectopic tachycardia | 0 | 1 (0.2) | 0 | 1 (0.1) | 1 (0.1) |
Orthostatic hypotension | 0 | 0 | 1 (0.3) | 1 (0.1) | 1 (0.1) |
Sinus tachycardia | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Supraventricular extrasystoles | 0 | 0 | 1 (0.3) | 1 (0.1) | 1 (0.1) |
Tachycardia | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Tricuspid valve incompetence | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Ventricular extrasystoles | 0 | 0 | 1 (0.3) | 1 (0.1) | 1 (0.1) |
Aged 40–49 years, n (%) | Placebo (n = 421) | Erenumab 70 mg (n = 356) | Erenumab 140 mg (n = 275) | Erenumab 70 + 140 mg (n = 631) | Total (N = 1052) |
Participants with CV/ cerebrovascular TEAEs | 10 (2.4) | 5 (1.4) | 7 (2.5) | 12 (1.9) | 22 (2.1) |
Hypertension | 2 (0.5) | 2 (0.6) | 1 (0.4) | 3 (0.5) | 5 (0.5) |
Palpitations | 2 (0.5) | 1 (0.3) | 2 (0.7) | 3 (0.5) | 5 (0.5) |
Extrasystoles | 1 (0.2) | 0 | 1 (0.4) | 1 (0.2) | 2 (0.2) |
Hot flush | 2 (0.5) | 0 | 0 | 0 | 2 (0.2) |
Arrhythmia | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Capillary fragility | 0 | 0 | 1 (0.4) | 1 (0.2) | 1 (0.1) |
Deep vein thrombosis | 0 | 1 (0.3) | 0 | 1 (0.2) | 1 (0.1) |
Haematoma | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Hypertensive crisis | 0 | 1 (0.3) | 0 | 1 (0.2) | 1 (0.1) |
Hypotension | 0 | 0 | 1 (0.4) | 1 (0.2) | 1 (0.1) |
Supraventricular tachycardia | 1 (0.2) | 0 | 0 | 0 | 1 (0.1) |
Thrombosis | 0 | 0 | 1 (0.4) | 1 (0.2) | 1 (0.1) |
Aged 50–59 years, n (%) | Placebo (n = 262) | Erenumab 70 mg (n = 214) | Erenumab 140 mg (n = 158) | Erenumab 70 + 140 mg (n = 372) | Total (N = 634) |
Participants with CV/ cerebrovascular TEAEs | 7 (2.7) | 4 (1.9) | 4 (2.5) | 8 (2.2) | 1 (0.2) |
Hot flush | 1 (0.4) | 1 (0.5) | 2 (1.3) | 3 (0.8) | 5 (0.8) |
Flushing | 0 | 1 (0.5) | 0 | 1 (0.3) | 4 (0.6) |
Hypertension | 4 (1.5) | 1 (0.5) | 0 | 1 (0.3) | 2 (0.3) |
Atrioventricular block first degree | 0 | 1 (0.5) | 0 | 1 (0.3) | 1 (0.2) |
Palpitations | 1 (0.4) | 0 | 1 (0.6) | 1 (0.3) | 1 (0.2) |
Peripheral coldness | 0 | 0 | 1 (0.6) | 1 (0.3) | 1 (0.2) |
Aged ≥ 60 years, n (%) | Placebo (n = 69) | Erenumab 70 mg (n = 38) | Erenumab 140 mg (n = 35) | Erenumab 70 + 140 mg (n = 73) | Total (N = 142) |
Participants with CV/ cerebrovascular TEAEs | 4 (5.8) | 2 (5.3) | 0 | 2 (2.7) | 6 (4.2) |
Hot flush | 1 (1.4) | 1 (2.6) | 0 | 1 (1.4) | 2 (1.4) |
Flushing | 1 (1.4) | 0 | 0 | 0 | 1 (0.7) |
Hypertensive crisis | 0 | 1 (2.6) | 0 | 1 (1.4) | 1 (0.7) |
Tachycardia | 1 (1.4) | 0 | 0 | 0 | 1 (0.7) |
Ventricular extrasystoles | 1 (1.4) | 0 | 0 | 0 | 1 (0.7) |